GREY by exceptionality defined as intolerance to the preferred 1st line choice (Lixisenatide) or restricted by their licensing. See local guidance for supporting material for prescribers.
RED: NICE TA664 - Liraglutide (Saxenda) for managing overweight and obesity. Prescribe by brand. Liraglutide is recommended as an option for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults, but it is restricted to prescribing in secondary care by a specialist multidisciplinary tier 3 weight management service with a commercial agreement in place. (Decision date - January 2021)